drugset / Trial / NCT06975111

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

NCT06975111

Phase 2/3 Recruiting 200 enrolled University of Colorado, Denver
Non-randomizedParallel-groupOpen-labelTreatment

Summary

What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.

Timeline

Start
2026-03-01
Primary completion
2029-10-31
Completion
2030-10-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule
Subject Fezolinetant Small molecule
Comparator Metformin Small molecule
Comparator Rosuvastatin Small molecule
Comparator Semaglutide Peptide